The subsets of T lymphocytes in thymus, spleen and mesenteric lymph nodes were investigated in normothermic and hyperthermic @entity19 treated with @entity2887 administered orally six times at 24 h intervals at doses of 15 or 75 mg/kg ( @entity22749 , @entity4258 and @entity2177 ) and 5 or 25 mg/kg ( @entity14116 ). It has been found that @entity2887 can modulate @entity5168 +, @entity1961 + and CD8+ marker expression on thymocytes, splenocytes and lymphocytes of mesenteric lymph nodes. @entity22749 (15 mg/kg) decreased the percentage of immature @entity1961 +CD8+ thymic cells and increased the percentage of mature @entity1961 + and CD8+. When the dose of @entity22749 was increased to 75 mg/kg a reduction in the maturation of thymocytes was observed. Administration of @entity22749 , @entity4258 and @entity2177 , irrespective of doses applied, increased the percentages of @entity5168 + splenocytes of @entity1961 + spleen cells. Exposure to @entity14116 decreased the percentage of T helper-inducer cells. @entity22749 and @entity2177 augmented the percentage of @entity5168 + mesenteric lymph node cells and increased the percentage of CD8+ cells. In contrast, @entity4258 and @entity14116 decreased the percentage of @entity5168 + mesenteric lymph node cells and the percentage of @entity1961 + cells. Lipopolysaccharide (LPS) from @entity526 (25 micro g/ @entity19 ) increased the percentage of single-positive @entity1961 + thymocytes, but did not affect the percentage of @entity5168 +, @entity1961 + and CD8+ splenocytes and mesenteric lymph node cells. @entity22749 and @entity2177 administered to @entity19 pior to LPS potentiated its stimulant effect on the maturation of thymic cells ( increased percentage of mature @entity1961 + and CD8+ thymocytes). Pre-treatment with @entity4258 or @entity14116 either reduced or did not modify the stimulant effect of LPS on maturation of thymic cells. @entity22749 , @entity4258 , @entity14116 and @entity2177 administered prior to LPS decreased the percentage of CD8+ splenocytes and increased the percentage of @entity1961 + spleen cells. @entity4258 and @entity2177 at a dose of 75 mg/kg reduced the percentage of CD8+ mesenteric lymph node cells in hyperthermic @entity19 . Pretreatment with @entity4258 at a dose of 15 mg/kg augmented the percentage of mesenteric lymph node cells. It was concluded that the modulating effects of @entity2887 depends on the chemial structure of drugs, dose administered as well as immunologic status.

Comparative effects of @entity2887 on subsets of T lymphocytes in normothermic and hyperthermic XXXX .

@entity4258 :: ('MESH:D009643', 'Chemical') :: ['Norfloxacin', 'norfloxacin'] @entity14116 :: ('MESH:C052904', 'Chemical') :: ['enrofloxacin'] @entity19 :: ('10090', 'Species') :: ['mice', 'mouse'] @entity5168 :: ('12501(Tax:10090)', 'Gene') :: ['CD3'] @entity2177 :: ('MESH:D002939', 'Chemical') :: ['ciprofloxacin'] @entity2887 :: ('MESH:D024841', 'Chemical') :: ['fluoroquinolones'] @entity1961 :: ('12504(Tax:10090)', 'Gene') :: ['CD4'] @entity22749 :: ('MESH:C012976', 'Chemical') :: ['flumequine', 'Flumequine'] @entity526 :: ('562', 'Species') :: ['E. coli']
@entity19 :: (10090,Species) :: ['mice']
